The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Supernus Pharmaceuticals Inc’s current trading price is 5.36% away from its 52-week high, while its distance from the 52-week low is 53.88%. The stock’s price range for this period has been between $27.58 and $40.28 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 3.81 million for the day, a number notably higher than the average daily volume of 0.66 million over the last three months.
At present, Supernus Pharmaceuticals Inc (SUPN) has a stock price of $42.44. In the previous session, the stock saw a rise, peaking at $46.0 after an opening price of $42.44. The day’s lowest price was $36.0, and it closed at $37.53.
Supernus Pharmaceuticals Inc ‘s stock market performance has been somewhat predictable.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Supernus Pharmaceuticals Inc (SUPN) has experienced a quarterly rise of 30.87% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.38B and boasts a workforce of 674 employees.
Supernus Pharmaceuticals Inc: What Analysts Are Saying
As of right now, 3 analysts are rating Supernus Pharmaceuticals Inc as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 32.53, with a change in price of +11.27. Similarly, Supernus Pharmaceuticals Inc recorded 641,996 in trading volume during the last 100 days, posting a change of +36.16%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for SUPN stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.02.
SUPN Stock Stochastic Average
Supernus Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 90.81%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 89.71%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 94.27% and 93.21%, respectively.
SUPN Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Year to date metric has recorded a gain of 47.46%.However, over the last six months, we can see a weaker performance of 6.10%. Over the last 30 days, the price of SUPN has fallen by 32.25%. And in the last five days, it has surged by 26.46%.
